CStone Pharmaceuticals
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSPHF research report →
Companywww.cstonepharma.com
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma.
- CEO
- Jianxin Yang
- IPO
- 2020
- Employees
- 135
- HQ
- Shanghai, CN
Price Chart
Valuation
- Market Cap
- $1.61B
- P/E
- -33.13
- P/S
- 44.63
- P/B
- 16.21
- EV/EBITDA
- -39.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 39.88%
- Op Margin
- -120.09%
- Net Margin
- -123.30%
- ROE
- -64.78%
- ROIC
- -28.27%
Growth & Income
- Revenue
- $262.63M · -35.51%
- Net Income
- $-425,725,766 · -366.77%
- EPS
- $-0.31 · -333.57%
- Op Income
- $-421,456,847
- FCF YoY
- 4.50%
Performance & Tape
- 52W High
- $1.01
- 52W Low
- $0.52
- 50D MA
- $0.97
- 200D MA
- $0.89
- Beta
- 0.25
- Avg Volume
- 161
Get TickerSpark's AI analysis on CSPHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CSPHF Coverage
We haven't published any research on CSPHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CSPHF Report →